Hypertrichosis of the eyelashes caused by bimatoprost - 24/08/11
Doi : 10.1016/j.jaad.2004.05.002
Antonella Tosti, MD a, ⁎ 
, Massimiliano Pazzaglia, MD a, Stylianos Voudouris, MD a, Giovanni Tosti, MD b
, Massimiliano Pazzaglia, MD a, Stylianos Voudouris, MD a, Giovanni Tosti, MD b a From the Department of Dermatology, University of Bologna
b Department of Ophthalmology, S. Luca Hospital, Trecenta
Reprint request: Antonella Tosti, MD, Department of Dermatology, University of Bologna, Via Massarenti no1, 40138 Bologna, Italy.Bologna and Trecenta-Rovigo, Italy
Abstract |
The phenyl-substituted analog of prostaglandin F2⍺, latanoprost (Xalatan; Pfizer, Inc, New York, NY) is an intraocular pressure (IOP)-lowering drug for use in patients with glaucoma and ocular hypertension. Latanoprost has been shown to stimulate eyelash hypertrichosis and has recently been proposed as a possible treatment for alopecia areata involving the eyelashes. We report a case of hypertrichosis of the eyelashes caused by the prostamide bimatoprost (Lumigan; Allergan, Inc, Irvine, Calif), a new IOP-lowering drug.
Le texte complet de cet article est disponible en PDF.Plan
| The pagination of this article was incorrect as originally published (2004:51;S77-S78). Please use the corrected page numbers listed online at http:www.eblue.org, in the corrected table of contents, or in the December 2004 index in future citations. This supplement is made possible through the generous support of Stiefel Laboratories for the American Academy of Dermatology. |
© 2004
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 51 - N° 5S
P. S149-S150 - novembre 2004 Retour au numéro
Article précédent
- Primary carcinoid tumor of the skin
- Clara-Dina Cokonis, Justin J. Green, Steven M. Manders
- Acute lymphoblastic leukemia presenting with urticarial plaques and hypereosinophilia in a child
- Andy J. Chien, Zsolt B. Argenyi, Roy M. Colven, Philip Kirby
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?